

# The Clinical Trial Matching & Pre-Screening (CTMP) Taskforce – A Work in Progress to Standardize and Enhance Pre-Screening and Referrals



Mili Ugrenovic-Petrovic, Jeff Edelman, Benjamin Tomas, Ashley Sansil, Pelumi Olaore, Sheila Interrante, Sevara Fazilova, Viviam Sifontes, Kim Sprenger, Fernando Bustamante, Vonny Ortega, Ana Aminpour, Lisa Nardelli, Jay Lebsack

## Background

Moffitt Cancer Center’s new patient volumes have increased **~6% each year**.

- The Clinical Trials Screening Coordinator (CTSC) role was established to match internal and external referrals to institution-wide clinical trials.
- In 2020, there were 3 CTSCs; currently, 14 CTSCs support programs across disease groups.
- Variation in clinical trial pre-screening and referral processes creates inefficiencies and inconsistent experiences for patients and team members.
- There is an opportunity to standardize both the CTSC role and referral processes to match patients to clinical trials.
- The CTMP taskforce was started 9/10/2025 to not only standardize the CTSC role at Moffitt but the whole referral process. This will result in a consistent experience for our patients, clinical teams, and our team members.

## Goals

- The overall taskforce finishes FY26 (6/30/26)
- The 8 groups consist of understanding and expanding the workflow, Moffitt Ambulatory Center (MAC) expansion and standardization, Community Provider Education, Nurse Navigator Integration, Patient & Family Inquiries, Tools & Technology needed for internal and external patient referrals, AI integration, Education and Onboarding, Handbook creation, and SOP development and refinement.

## Education, Onboarding, & Tool Rollout

### Clinical Trials Screening Coordinator Training Overview



## Outcomes

- CTSCs now attend applicable marketing events to aid in meeting local physicians and sharing available trials.
- CTSCs collaborate across disease programs to find the best fit for the patient with the PI and treating physician. For example, the CTSCs in GI, Early Therapeutics, MACs, and Immune Cell Therapy have all met to review trial options for patients across portfolios and provide 1 contact for the patient.
- Finally, the taskforce has brought different teams together like nurse navigators, field marketing, CTSCs, and community education.

## Solutions and Methods

- Each team has a lead and meets at least monthly.
- Milestones and a decision log are tracked to summarize completed key steps and next direction.
- All members of the taskforce meet together bimonthly to report team updates.

## Refinements and Next Steps

- Structured evaluation and piloting of emerging clinical trial matching technologies.
- The evaluation criteria will continue to focus on clinical feasibility, operational fit, data transparency, and equity in clinical trial access.
- Tools and workflows created in the CTMP taskforce will be further refined and incorporated across disease programs and our MACs.
- Determine future usage in the AI integration world.

### Screening Explorer Tool Integrated into Disease Programs

Welcome to the Malignant Hematology Clinical Trials Explorer, designed to provide updated and relevant information about the clinical trials available at Moffitt Cancer Center. This tool serves as a guide for providers and partner clinics seeking innovative treatment options for their patients.

Next to each internal study number (identifier used at Moffitt), you will find the corresponding NCT code for additional references on [clinicaltrials.gov](#)

If you have any questions or wish to initiate a referral process, please feel free to contact directly Fernando Bustamante, Clinical Trials Screening Coordinator at [Fernando.Bustamante@moffitt.org](mailto:Fernando.Bustamante@moffitt.org) or (813) 745 5336.

Nuestro equipo está capacitado para asistir en español. Para consultas adicionales o apoyo en el proceso de referencia, puede contactar a Fernando Bustamante, Coordinador de Evaluación de Programas para Estudios Clínicos, a través del correo [Fernando.Bustamante@moffitt.org](mailto:Fernando.Bustamante@moffitt.org) o llamando al (813) 745 5336.

Disease group: Myeloid

Myeloid Clinical Trials

AML Relapsed/Refractory

AML Relapsed/Refractory: Non-intensive approach

